Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drugs may shield against severe pneumonia outcomes

NCT ID NCT07708610

Knowledge-focused Sponsor: Chung Shan Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at whether taking a combination of GLP-1 receptor agonists and SGLT2 inhibitors before being hospitalized with pneumonia improves early outcomes in adults with type 2 diabetes. Researchers analyzed health records from over 70,000 patients, comparing those on both drugs to those on one or neither. The goal is to see if these medications reduce the risk of death, need for a breathing machine, or kidney replacement therapy within 30 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonists and SGLT2 inhibitors (glucose-lowering drugs)
What this could lead to
If these drugs improve pneumonia outcomes, it could point to better treatment strategies for people with type 2 diabetes hospitalized with pneumonia.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. The findings need confirmation in prospective studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 71,775 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults will be selected from the TriNetX US Collaborative Network, a distributed database of de-identified electronic health records contributed by participating healthcare organizations across multiple clinical systems and practice settings. The study population consists of adults with type 2 diabetes who were hospitalized with pneumonia and received routine clinical care in this network, identified through diagnosis records, laboratory data, encounter records, and medication prescribing data. Comparator-specific cohorts were defined within this source population according to glucose-lowering prescriptions recorded in the year before the index admission, to evaluate preadmission GLP-1 receptor agonist- and SGLT2 inhibitor-based treatment strategies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Type 2 diabetes mellitus * Hospitalization with pneumonia during the study period, serving as the index admission * Prescription of a GLP-1 receptor agonist, an SGLT2 inhibitor, or usual-care glucose-lowering therapy in the year before the index admission * No GLP-1 receptor agonist or SGLT2 inhibitor prescription in the 6 months before the first qualifying prescription Exclusion Criteria: * Type 1 diabetes mellitus, or other specified diabetes types that are not type 2 diabetes * Human immunodeficiency virus infection * Bariatric surgery * Solid-organ transplantation * Pneumonia hospitalization, invasive mechanical ventilation, or renal replacement therapy in the year before the index admission * End-stage kidney disease, dialysis dependence, ventilator dependence, or tracheostomy status * Metastatic malignancy, lung cancer, or palliative care * Viral pneumonia, influenza with pneumonia, or COVID-19 around the index admission * Acute cardiovascular event in the 6 months before the index admission

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumonia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumonia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumonia Type 2 diabetes mellitus (T2DM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chung Shan Medical University Hospital

    Taichung, Taichung, 402, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.